CollPlant Biotechnologies (CLGN) EV to EBITDA (2018 - 2026)

CollPlant Biotechnologies (CLGN) has reported EV to EBITDA for 9 consecutive years, with 0.24 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, EV to EBITDA rose 86.32% year-over-year to 0.24; the trailing twelve-month figure through Mar 2026 stood at 0.11 (up 77.42% YoY), and the FY2025 full-year result was 0.36, down 22.25% from the prior year.
• EV to EBITDA slipped to 0.24 in Q1 2026 per CLGN's latest filing, from 1.32 in the prior quarter.
• Across five years, EV to EBITDA topped out at 18.67 in Q2 2022 and bottomed at 15.7 in Q1 2022.
• Historically, EV to EBITDA has averaged 1.14 across 5 years, with a median of 1.32 in 2025.
• The widest YoY moves for EV to EBITDA: up 1860.36% in 2022, down 1390.62% in 2022.
• Over 5 years, EV to EBITDA stood at 4.35 in 2022, then dropped by 11.09% to 3.87 in 2023, then sank by 47.72% to 2.02 in 2024, then tumbled by 34.71% to 1.32 in 2025, then plunged by 118.37% to 0.24 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 0.24, 1.32, and 1.64 for Q1 2026, Q4 2025, and Q3 2025 respectively.